Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release

The mechanism by which physostigmine exerts its behavioral, neuroendocrine and cardiovascular effects was explored in two separate experiments. In the first, the centrally-acting cholinesterase inhibitor physostigmine was compared with the non-centrally-acting agent neostigmine. In contrast to physo...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 1986-01, Vol.89 (2), p.150-154
Main Authors: JANOWSKY, D. S, RISCH, S. C, KENNEDY, B, ZIEGLER, M, HUEY, L
Format: Article
Language:English
Subjects:
Adrenal Cortex - drug effects
Adult
Animals
Biological and medical sciences
Blood Pressure - drug effects
Cardiovascular System - drug effects
Cholinergic system
Emotions - drug effects
Female
Humans
Male
Medical sciences
Middle Aged
Neostigmine - pharmacology
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
Physostigmine - pharmacology
Pituitary Gland - drug effects
Rats
Receptors, Muscarinic - drug effects
Receptors, Nicotinic - drug effects
Scopolamine - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mechanism by which physostigmine exerts its behavioral, neuroendocrine and cardiovascular effects was explored in two separate experiments. In the first, the centrally-acting cholinesterase inhibitor physostigmine was compared with the non-centrally-acting agent neostigmine. In contrast to physostigmine, neostigmine caused no effects. In the second experiment, pretreatment with scopolamine, in contrast to methscopolamine, attenuated physostigmine's effects. The results suggest that physostigmine exerts its effects via a central muscarinic mechanism.
ISSN:0033-3158
1432-2072
DOI:10.1007/BF00310619